Journal of Pediatric Neurology 2021; 19(04): 235-239
DOI: 10.1055/s-0040-1708833
Original Article

Neuroprotective Efficacy of Prophylactic Antiepileptic Therapies in Busulfan Conditioning Regimen

1   Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey
,
Murat Elli
2   Division of Pediatric Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey
,
Ömer F. Aydin
1   Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey
,
Canan Albayrak
2   Division of Pediatric Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey
,
Davut Albayrak
2   Division of Pediatric Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey
,
Emel Özyürek
2   Division of Pediatric Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey
› Institutsangaben

Abstract

Busulfan (BU) is commonly used in the anticancer treatment and bone marrow/hematopoietic stem cell transplantation (BM/HSCT) conditioning regimen. This study aimed to evaluate the neuroprotective efficacy of antiepileptic therapies in the BU conditioning regimen. Patients who underwent BM/HSCT between January 1, 2009, and January 1, 2014, were evaluated retrospectively. Diagnosis, demographic characteristics, neurological side effects, electroencephalography (EEG) abnormalities, and antiepileptic drugs were determined. Levetiracetam was given to 49% and phenytoin to 23% of patients as antiepileptic prophylaxis. After BU treatment, seizures developed in three patients, posterior reversible leukoencephalopathy in two patients, and peripheral neuropathy in two patients. Forty-five patients who underwent EEG before and after BU treatment were identified. The effects of antiepileptic prophylaxis over the electroencephalographic abnormalities after the BU conditioning regimen were found to be not different (p = 0.491). Neurological side effects and electroencephalographic abnormalities following BU conditioning regimen under antiepileptic prophylaxis are comparable.



Publikationsverlauf

Eingereicht: 16. Januar 2020

Angenommen: 23. Februar 2020

Artikel online veröffentlicht:
17. April 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Guichard N, Bonnabry P, Rudaz S, Fleury-Souverain S. Stability of busulfan solutions in polypropylene syringes and infusion bags as determined with an original assay. Am J Health Syst Pharm 2017; 74 (22) 1887-1894
  • 2 Ben-Barouch S, Cohen O, Vidal L, Avivi I, Ram R. Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis. Bone Marrow Transplant 2016; 51 (02) 232-240
  • 3 Pulsipher MA, Boucher KM, Wall D. et al. Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood 2009; 114 (07) 1429-1436
  • 4 Carreras E, Cahn JY, Puozzo C. et al. Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. Anticancer Res 2010; 30 (07) 2977-2984
  • 5 Hamidieh AA, Hamedani R, Hadjibabaie M, Amini M, Sadrai S, Ghavamzadeh A. Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. Pediatr Hematol Oncol 2010; 27 (07) 529-533
  • 6 Akiyama K, Kume T, Fukaya M. et al. Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients. Cancer Chemother Pharmacol 2018; 82 (04) 717-721
  • 7 Product monography PrDilantin® (30 mg Extended Phenytoin Sodium Capsules, Manufacturer Standard, 100 mg Extended Phenytoin Sodium Capsules USP) anticonvulsant. ® Warner-Lambert Company LLC Pfizer Canada Inc, Licensee Kirkland, Quebec H9J 2M5. Date of revision January 23, 2019
  • 8 Sirsi D, Safdieh JE. The safety of levetiracetam. Expert Opin Drug Saf 2007; 6 (03) 241-250
  • 9 Perrenoud M, André P, Buclin T, Decosterd LA, Rossetti AO, Novy J. Levetiracetam circulating concentrations and response in status epilepticus. Epilepsy Behav 2018; 88: 61-65
  • 10 Han JY, Moon CJ, Youn YA, Sung IK, Lee IG. Efficacy of levetiracetam for neonatal seizures in preterm infants. BMC Pediatr 2018; 18 (01) 131
  • 11 KEPPRA® (levetiracetam) 250 mg, 500 mg, 750 mg, and 1000 mg tablets 100 mg/mL oral solution. FDA Approved Label. Accessed February 2, 2018 at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021035s078s080,021505s021s024lbl.pdf
  • 12 Brigo F. Intermittent rhythmic delta activity patterns. Epilepsy Behav 2011; 20 (02) 254-256
  • 13 Britton JW, Frey LC, Hoop JL. et al. The abnormal EEG. In: St. Louis EK, Frey LC, eds. Electroencephalography (EEG): An Introductory Text and Atlas of normal and Abnormal Findings in Adults, Children, and Infants. Chicago: American Epilepsy Society; 2016
  • 14 Kobayashi R, Watanabe N, Iguchi A. et al. Electroencephalogram abnormality and high-dose busulfan in conditioning regimens for stem cell transplantation. Bone Marrow Transplant 1998; 21 (03) 217-220
  • 15 Caselli D, Ziino O, Bartoli A, Santangelo G, Vanadia F, Aricò M. Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan. Bone Marrow Transplant 2008; 42 (02) 135-136
  • 16 Nath CE, Shaw PJ. Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring. Curr Clin Pharmacol 2007; 2 (01) 75-91
  • 17 Myers AL, Kawedia JD, Champlin RE. et al. Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. Expert Opin Drug Metab Toxicol 2017; 13 (09) 901-923
  • 18 Bartelink IH, Lalmohamed A, van Reij EM. et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol 2016; 3 (11) e526-e536
  • 19 Caselli D, Rosati A, Faraci M. et al; Bone Marrow Transplantation Working Group of the Associazione Italiana Ematologia Oncologia Pediatrica. Risk of seizures in children receiving busulphan-containing regimens for stem cell transplantation. Biol Blood Marrow Transplant 2014; 20 (02) 282-285
  • 20 Kim B, Lee JW, Hong KT. et al. Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients. Sci Rep 2017; 7 (01) 1711
  • 21 Watanabe E, Nishikawa T, Ikawa K. et al. Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients. Int J Hematol 2015; 102 (05) 611-616
  • 22 Trame MN, Bergstrand M, Karlsson MO, Boos J, Hempel G. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. Clin Cancer Res 2011; 17 (21) 6867-6877
  • 23 Ansari M, Huezo-Diaz P, Rezgui MA. et al. Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients. Bone Marrow Transplant 2016; 51 (03) 377-383
  • 24 Mehta PA, Emoto C, Fukuda T. et al. Busulfan pharmacokinetics and precision dosing: are patients with Fanconi anemia different?. Biol Blood Marrow Transplant 2019; 25 (12) 2416-2421
  • 25 Bertholle-Bonnet V, Bleyzac N, Galambrun C. et al. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study. Ther Drug Monit 2007; 29 (02) 177-184
  • 26 Nath CE, Earl JW, Pati N, Stephen K, Shaw PJ. Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients. Br J Clin Pharmacol 2008; 66 (01) 50-59
  • 27 Chiesa R, Cappelli B, Crocchiolo R. et al. Unpredictability of intravenous busulfan pharmacokinetics in children undergoing hematopoietic stem cell transplantation for advanced beta thalassemia: limited toxicity with a dose-adjustment policy. Biol Blood Marrow Transplant 2010; 16 (05) 622-628